InterCure Ltd. (TLV:INCR)
Israel · Delayed Price · Currency is ILS · Price in ILA 420.80
+1.00 (0.24%)
At close: Dec 7, 2025
InterCure Revenue
InterCure had revenue of 65.01M ILS in the half year ending June 30, 2025, with 3.40% growth. This brings the company's revenue in the last twelve months to 243.12M, down -10.84% year-over-year. In the year 2024, InterCure had annual revenue of 238.85M, down -32.82%.
Revenue (ttm)
243.12M
Revenue Growth
-10.84%
P/S Ratio
0.94
Revenue / Employee
759.76K
Employees
320
Market Cap
229.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 238.85M | -116.71M | -32.82% |
| Dec 31, 2023 | 355.55M | -33.13M | -8.52% |
| Dec 31, 2022 | 388.68M | 169.01M | 76.93% |
| Dec 31, 2021 | 219.68M | 154.64M | 237.78% |
| Dec 31, 2020 | 65.04M | 56.11M | 628.60% |
| Dec 31, 2019 | 8.93M | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 55.55B |
| Danel (Adir Yeoshua) | 2.87B |
| Novolog (Pharm-Up 1966) | 1.97B |
| Ilex Medical | 915.05M |
| Kamada | 578.74M |
| SofWave Medical | 255.13M |
| BrainsWay | 162.56M |
| Bait Bakfar | 107.78M |